tetano
Editor, Senior Moderator
Immunotherapy. 2020 May 12. doi: 10.2217/imt-2020-0095. [Epub ahead of print]
Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens.
D?ez JM[SUP]1[/SUP], Romero C[SUP]1[/SUP], Gajardo R[SUP]1[/SUP].
Author information
Abstract
Aim: There is a critical need for effective therapies that are immediately available to control the spread of COVID-19 disease. Material & methods: Gamunex[SUP]?[/SUP]-C and Flebogamma[SUP]?[/SUP] DIF (Grifols) intravenous immunoglobulin (IVIG) products were tested using ELISA techniques for antibodies against several antigens of human common betacoronaviruses that may crossreact with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Results: Both IVIGs showed consistent reactivity to components of the tested viruses. Positive crossreactivity was seen in SARS-CoV, middle east respiratory syndrome-CoV and SARS-CoV-2. For SARS-CoV-2, positive reactivity was observed at IVIG concentrations ranging from 100 μg/ml with Gamunex-C to 1 mg/ml with Flebogamma 5% DIF. Conclusion: Gamunex-C and Flebogamma DIF contain antibodies reacting against SARS-CoV-2 antigens. Studies to confirm the utility of IVIG preparations for COVID-19 management may be warranted.
KEYWORDS:
COVID-19; SARS-CoV-2; antibody content; intravenous immunoglobulin
PMID:32397847DOI:10.2217/imt-2020-0095
Free PMC Article
Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens.
D?ez JM[SUP]1[/SUP], Romero C[SUP]1[/SUP], Gajardo R[SUP]1[/SUP].
Author information
Abstract
Aim: There is a critical need for effective therapies that are immediately available to control the spread of COVID-19 disease. Material & methods: Gamunex[SUP]?[/SUP]-C and Flebogamma[SUP]?[/SUP] DIF (Grifols) intravenous immunoglobulin (IVIG) products were tested using ELISA techniques for antibodies against several antigens of human common betacoronaviruses that may crossreact with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Results: Both IVIGs showed consistent reactivity to components of the tested viruses. Positive crossreactivity was seen in SARS-CoV, middle east respiratory syndrome-CoV and SARS-CoV-2. For SARS-CoV-2, positive reactivity was observed at IVIG concentrations ranging from 100 μg/ml with Gamunex-C to 1 mg/ml with Flebogamma 5% DIF. Conclusion: Gamunex-C and Flebogamma DIF contain antibodies reacting against SARS-CoV-2 antigens. Studies to confirm the utility of IVIG preparations for COVID-19 management may be warranted.
KEYWORDS:
COVID-19; SARS-CoV-2; antibody content; intravenous immunoglobulin
PMID:32397847DOI:10.2217/imt-2020-0095
Free PMC Article